GlobeNewswire Inc | Mar 4, 2021 07:30AM EST

March 04, 2021

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Companys Executive Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 10, 2021. The presentation will be accessible for on-demand download beginning on Tuesday, March 9, 2021 at 7:00 AM ET.

A replay of this presentation will be available on the Events page, located within the Investors & Media section, of the Companys website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS, INC.TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from theU.S.FDA for UKONIQ(umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has two programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development.For more information,visitwww.tgtherapeutics.com, and follow us on Twitter@TGTherapeuticsandLinkedin.

UKONIQ is a trademark ofTG Therapeutics, Inc.

CONTACT: Investor Relations Email: ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations: Email: media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 6